The genesis and evolution of high-grade serous ovarian cancer (Q55053523)

16 June 2018

title

The genesis and evolution of high-grade serous ovarian cancer (English)

1 reference

1 August 2024

1 reference

1 reference

16 June 2018

language of work or name

English

0 references

publication date

14 October 2010

1 reference

16 June 2018

full work available at URL

http://www.nature.com/articles/nrc2946.pdf

file format

Portable Document Format

1 reference

http://www.nature.com/articles/nrc2946

1 August 2024

1 reference

1 August 2024

published in

Nature Reviews Cancer

1 reference

16 June 2018

volume

1 reference

16 June 2018

issue

1 reference

16 June 2018

page(s)

803-808

1 reference

16 June 2018

Colorectal cancer: a multipathway disease

cites work

1 reference

Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation

21 January 2018

1 reference

The biology of ovarian cancer: new opportunities for translation

21 January 2018

1 reference

Histopathologic grading of ovarian carcinoma: a review and proposal

31 March 2020

1 reference

The distinction between primary and metastatic mucinous carcinomas of the ovary: gross and histologic findings in 50 cases

31 March 2020

1 reference

Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer

31 March 2020

1 reference

Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome

31 March 2020

1 reference

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies

31 March 2020

1 reference

Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems

31 March 2020

1 reference

A candidate precursor to serous carcinoma that originates in the distal fallopian tube.

31 March 2020

1 reference

Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancer

31 March 2020

1 reference

A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations

31 March 2020

1 reference

Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer.

31 March 2020

1 reference

Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma

31 March 2020

1 reference

Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon.

31 March 2020

1 reference

Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.

31 March 2020

1 reference

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary

31 March 2020

1 reference

Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada

31 March 2020

1 reference

Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment

31 March 2020

1 reference

Frequency of BRCA1 dysfunction in ovarian cancer

31 March 2020

1 reference

Inactivation of BRCA1 and BRCA2 in ovarian cancer

31 March 2020

1 reference

Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer

31 March 2020

1 reference

Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway

31 March 2020

1 reference

Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities

31 March 2020

1 reference

Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers

31 March 2020

1 reference

Involvement of Brca2 in DNA repair

31 March 2020

1 reference

Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells

31 March 2020

1 reference

The Li-Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tube

31 March 2020

1 reference

Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis.

31 March 2020

1 reference

BRCA1 and FOXA1 proteins coregulate the expression of the cell cycle-dependent kinase inhibitor p27(Kip1)

31 March 2020

1 reference

BRCA1 transactivates the cyclin-dependent kinase inhibitor p27(Kip1)

31 March 2020

1 reference

EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer

31 March 2020

1 reference

Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas

31 March 2020

1 reference

Large-scale genomic analysis of ovarian carcinomas

31 March 2020

1 reference

Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas

31 March 2020

1 reference

High-resolution analysis of copy number alterations and associated expression changes in ovarian tumors

31 March 2020

1 reference

Tiling path genomic profiling of grade 3 invasive ductal breast cancers

31 March 2020

1 reference

Basal-like subtype of breast cancer: a review of its unique characteristics and their clinical significance

31 March 2020

1 reference

High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors

31 March 2020

1 reference

High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.

31 March 2020

1 reference

Complex landscapes of somatic rearrangement in human breast cancer genomes

31 March 2020

1 reference

Genome-wide analysis of DNA copy-number changes using cDNA microarrays

31 March 2020

1 reference

Mitotic checkpoint inactivation fosters transformation in cells lacking the breast cancer susceptibility gene, Brca2.

31 March 2020

1 reference

Cancer as an evolutionary and ecological process

31 March 2020

1 reference

MYC as a regulator of ribosome biogenesis and protein synthesis

31 March 2020

1 reference

A mouse model for cyclin E-dependent genetic instability and tumorigenesis

31 March 2020

1 reference

Deregulated cyclin E induces chromosome instability

31 March 2020

1 reference

DNA methylome of familial breast cancer identifies distinct profiles defined by mutation status

31 March 2020

1 reference

International network of cancer genome projects

31 March 2020

1 reference

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors

31 March 2020

1 reference

Resistance to therapy caused by intragenic deletion in BRCA2

31 March 2020

1 reference

Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance

31 March 2020

1 reference

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

31 March 2020

1 reference

Hallmarks of 'BRCAness' in sporadic cancers

31 March 2020

1 reference

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

31 March 2020

1 reference

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

31 March 2020

1 reference

Novel candidate targets of beta-catenin/T-cell factor signaling identified by gene expression profiling of ovarian endometrioid adenocarcinomas.

31 March 2020

1 reference

12 December 2020

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

1 reference

12 December 2020

Mapping the cancer genome. Pinpointing the genes involved in cancer will help chart a new course across the complex landscape of human malignancies.

1 reference

12 December 2020

The Fanconi Anemia/BRCA signaling pathway: disruption in cisplatin-sensitive ovarian cancers.

1 reference

12 December 2020

The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations.

1 reference

12 December 2020

2913

DR Schwartz

2003

1 reference

1 August 2024

Identifiers

DOI

10.1038/NRC2946

1 reference

16 June 2018

Dimensions Publication ID

1009226044

0 references

1 reference

16 June 2018